logo-loader
RNS
Feedback PLC

Feedback PLC - New tuberculosis partnership in India

RNS Number : 0594I
Feedback PLC
25 March 2024
 

Feedback plc

 

New tuberculosis partnership in India

 

·      Partnership focused on delivering CSR and donor funded screening projects

·      Aim to develop a digital model that is able to scale at pace

 

Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the clinical infrastructure specialist, announces a new partnership with the HEAL Foundation in India, to deliver community based TB screening projects, funded initially by third-party donors, to support the government's goal of eradicating tuberculosis ("TB") by 2025.

 

With the Company's unique field-based diagnostic and pathway capabilities and HEAL Foundation's pioneering on-the ground approach, the aim is to bring a 21st century screening service to every community in India, even to the most remote of communities. The focus of this partnership is to develop and drive a digital model, that is able to scale at pace, and build the case for increasing the role of technology to deliver TB screening in India, which has a population of over one billion. This will likely initially be in the form of part-funded pilot studies, which the Company anticipates would cover its core project costs, to validate the digital model ahead of commercial contracts.

 

Feedback is aiming to provide India with a digital first screening model that harnesses the speed and accuracy of X-ray imaging, supported by AI diagnostics. Effective screening requires asymptomatic cases in all areas of society, and we believe the only way to deliver this is via X-ray imaging performed right in the heart of the community.

 

HEAL Foundation, as a non-governmental organisation ("NGO") will be the contracting entity with the donor organisations to receive funds. The partnership envisages that HEAL Foundation will provide project management and on-the-ground delivery of the TB screening projects - with Feedback, through its local subsidiary Feedback Medical India PVT Ltd, being the end-to-end technology partner (including selection and appointment of an AI provider, where appropriate) for TB screening and referral pathways.

 

HEAL Foundation is a not-for-profit organisation registered under the Indian Trust Act. As a trust, it aims to engage key stakeholders of the healthcare industry in India.  

 

Rohit Singh, Managing Director of Feedback Medical India PVT Ltd said: "It is clear that TB screening needs a new model - and the only approach is a digitally enabled service, ideally with a digital front door and Bleepa is that enabler.

 

"We look forward to working with HEAL Foundation and in time believe we can adapt the screening model and together build a business case for increasing the role of technology in future projects. It is essential that we can demonstrate the benefits around delivery and scalability in order to help donors understand that technology is a critical component for delivering social impact in this space.

 

"We are extremely excited by this partnership - with World TB Day yesterday, further raising public awareness about the devastating health, social and economic consequences of TB, we very much hope to be part of the solution in India." 

 

--Ends--

Enquiries:

 

Feedback plc

Tom Oakley, CEO

Anesh Patel, CFO

+44 (0) 20 3997 7634

IR@fbk.com

 


Panmure Gordon (UK) Limited (NOMAD and Broker)

Emma Earl/Freddy Crossley (Corporate Finance)

Rupert Dearden (Corporate Broking)

+44 (0)20 7886 2500

 


Walbrook PR Ltd;

Tel: 020 7933 8780 or feedbackplc@walbrookpr.com

Nick Rome/Joe Walker

07748 325 236 or 07407 020 470

 

 

About Feedback

 

Feedback plc helps clinical teams to make better decisions faster for patients. We design products that enhance clinician access to patient data and to their colleagues. Our unique approach centres around individual patient episodes, into which we pull relevant clinical data from hospital systems and around which we build remote clinical teams for collaboration. As a result, we produce a digital infrastructure that makes patient data available to clinicians in multiple settings, in a format that enables them to meaningfully interact with it, providing flexibility to clinicians and free movement of patients between provider settings - clinicians can practice from anywhere and patients can attend any care provider for treatment. 

 

Our products Bleepa and CareLocker work together to deliver unparalleled value to our customers. Bleepa is our application layer and sits on top of CareLocker as our data layer. Bleepa is a clinician facing platform that displays clinical results from a patient's CareLocker at a certified and regulated quality, that is suitable for clinical use and enables dialogue on a patient-by-patient basis with colleagues through a secure, auditable chat interface that links back to the patient medical record. The CareLocker data storage model is built around the patient. Our vision is one where relevant clinical data is always available to the patient as well as to any care setting that they may attend - a federated data architecture with the patient as the tenant.  

 

The Company has a number of growth opportunities domestically and internationally across a range of markets including the NHS, the veterinary market and private healthcare providers and its highly scalable Software as a Service ("SaaS")-based model is expected to provide increasing levels of revenue visibility as the Company grows its customer base.

 

About HEAL Foundation

 

HEAL Foundation is a not-for-profit organisation registered under the Indian Trust Act. As a trust, it aims to engage key stakeholders of the healthcare industry in India. 

 

About Us - healfoundation

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDQKQBDDBKBKNB
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

5 min read